Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics.
Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities.
The company was founded in 2011 and is headquartered in Vancouver, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 19, 25 | -0.25 Increased by 0.00% | -0.22 Decreased by -11.71% |
| Nov 12, 24 | -0.24 Decreased by -0.50% | -0.21 Decreased by -14.86% |
| Aug 14, 24 | -0.22 Increased by +51.11% | -0.19 Decreased by -15.79% |
| May 14, 24 | -0.22 Increased by +15.38% | -0.21 Decreased by -4.76% |
| Mar 21, 24 | -0.25 Decreased by -19.05% | -0.25 |
| Nov 14, 23 | -0.24 Increased by +20.00% | -0.23 Decreased by -4.35% |
| Aug 14, 23 | -0.45 Decreased by -40.63% | -0.24 Decreased by -87.50% |
| May 15, 23 | -0.26 Increased by +21.21% | -0.24 Decreased by -8.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 665.00 K Increased by +96.75% | -28.98 M Decreased by -23.10% | Decreased by -4.36 K% Increased by +37.43% |
| Sep 30, 24 | 1.70 M Increased by +128.63% | -27.40 M Decreased by -24.57% | Decreased by -1.61 K% Increased by +45.51% |
| Jun 30, 24 | 1.27 M Decreased by -62.28% | -24.75 M Increased by +40.61% | Decreased by -1.95 K% Decreased by -57.46% |
| Mar 31, 24 | 898.00 K Decreased by -29.24% | -21.98 M Increased by +5.91% | Decreased by -2.45 K% Decreased by -32.96% |
| Dec 31, 23 | 338.00 K Decreased by -78.29% | -23.55 M Decreased by -20.92% | Decreased by -6.97 K% Decreased by -457.03% |
| Sep 30, 23 | 744.00 K Decreased by -68.59% | -21.99 M Increased by +19.31% | Decreased by -2.96 K% Decreased by -156.91% |
| Jun 30, 23 | 3.37 M Increased by +236.03% | -41.67 M Decreased by -45.30% | Decreased by -1.24 K% Increased by +56.76% |
| Mar 31, 23 | 1.27 M Increased by +54.95% | -23.36 M Increased by +20.81% | Decreased by -1.84 K% Increased by +48.89% |